Clinicians should continue to monitor UACR or UPCR in at-risk children. During periods of rapid growth such as puberty, children with low GFR may show rapid decline in kidney function. Puberty is a ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...